Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms? Publisher Pubmed



Rahmatidehkordi F1, 2, 3 ; Birang N4 ; Jalalian MN5 ; Tamtaji Z6 ; Dadgostar E7, 8 ; Aschner M9 ; Shafiee Ardestani M10 ; Jafarpour H11 ; Mirzaei H12 ; Nabavizadeh F2, 3 ; Tamtaji OR2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
  7. 7. Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  8. 8. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  9. 9. Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, 10461, NY, United States
  10. 10. Department of Radio Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  11. 11. Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  12. 12. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

Source: Naunyn-Schmiedeberg's Archives of Pharmacology Published:2025


Abstract

Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.